Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2010-02-17

FDA Approved: NORVASC — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

FDA approved a supplemental application for NORVASC (amlodipine besylate) submitted by Viatris Specialty LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NORVASC (amlodipine besylate)

Snippet

SUPPL AP for NORVASC (AMLODIPINE BESYLATE)